Drug Monograph
MVASI
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Your search for bevacizumab returned 23 results
Drug Monograph
ZIRABEV
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Drug Monograph
AVASTIN
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
News
Low Doses of Bevacizumab Tested for Retinopathy of Prematurity
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
News
Immunotherapy Regimen Approved for Hepatocellular Carcinoma
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
News
Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
News, Oncology
QoL Extended With Atezolizumab + Bevacizumab in Liver Cancer
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
News
Anti-VEGF Injections May Reduce Glaucoma Burden for Some
Study shows reductions in intraocular pressures and antiglaucoma medication use.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
